Rocket Pharmaceuticals (NASDAQ:RCKT) & Genprex (NASDAQ:GNPX) Head-To-Head Contrast

Genprex (NASDAQ:GNPX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation & Earnings

This table compares Genprex and Rocket Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$30.86 million	N/A	N/A
Rocket Pharmaceuticals	N/A	N/A	-$245.60 million	($2.87)	-6.63

Profitability

This table compares Genprex and Rocket Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-318.57%	-224.95%
Rocket Pharmaceuticals	N/A	-54.47%	-47.99%

Analyst Ratings

This is a summary of current recommendations for Genprex and Rocket Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	0	0	1	0	3.00
Rocket Pharmaceuticals	0	1	9	0	2.90

Genprex currently has a consensus target price of $10.00, suggesting a potential upside of 1,983.77%. Rocket Pharmaceuticals has a consensus target price of $51.75, suggesting a potential upside of 171.94%. Given Genprex’s stronger consensus rating and higher possible upside, research analysts plainly believe Genprex is more favorable than Rocket Pharmaceuticals.

Risk and Volatility

Genprex has a beta of -0.57, indicating that its share price is 157% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Institutional & Insider Ownership

14.1% of Genprex shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 11.5% of Genprex shares are owned by company insiders. Comparatively, 31.1% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Rocket Pharmaceuticals beats Genprex on 6 of the 9 factors compared between the two stocks.

About Genprex

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.